Pharming Group (NASDAQ:PHAR) Stock Price Up 6.3% – Time to Buy?

Pharming Group (NASDAQ:PHAR)’s share price rose 6.3% during mid-day trading on Tuesday . The company traded as high as $8.26 and last traded at $8.47. Approximately 8,763 shares changed hands during trading, an increase of 45% from the average daily volume of 6,025 shares. The stock had previously closed at $7.96.

Analysts Set New Price Targets

Several research firms recently weighed in on PHAR. Jefferies Financial Group started coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, December 17th.

Pharming Group Price Performance

The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The business has a fifty day moving average of $9.05 and a two-hundred day moving average of $8.57. The firm has a market capitalization of $594.59 million, a price-to-earnings ratio of -33.62 and a beta of -0.10.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. As a group, research analysts predict that Pharming Group will post -0.2 EPS for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in shares of Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.